Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells

  • Authors:
    • Motoyoshi Tanaka
    • H. Barton Grossman
  • View Affiliations

  • Published online on: February 1, 2004     https://doi.org/10.3892/or.11.2.537
  • Pages: 537-541
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Connexin 26 (Cx26) encodes a gap junction protein and is a putative tumor suppressor gene. We evaluated the effect of forced expression of Cx26 on three human prostate cancer cell lines, PC-3, LNCap, and DU-145. The three cell lines were infected with a Cx26 adenovirus vector (Ad-Cx26) or a control vector or were mock infected. We tested cell growth, cell cycle, apoptosis, and the efficacy of combined treatment with doxorubicin. Ad-Cx26 infection suppressed the growth of all the cell lines compared with controls and induced cell cycle arrest at the G2/M phase and apoptosis. Ad-Cx26 decreased the expression of Bcl-2. LNCaP cell growth was dramatically suppressed by Ad-Cx26 alone. PC-3 and DU-145 had greater growth suppression with combined gene therapy and chemotherapy than with either Ad-Cx26 or doxorubicin alone. Forced expression of Cx26 suppresses the growth of prostate cancer cells and decreases the expression of Bcl-2. Combining Cx26 gene therapy with doxorubicin results in greater growth suppression.

Related Articles

Journal Cover

February 2004
Volume 11 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tanaka, M., & Tanaka, M. (2004). Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells. Oncology Reports, 11, 537-541. https://doi.org/10.3892/or.11.2.537
MLA
Tanaka, M., Grossman, H. B."Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells". Oncology Reports 11.2 (2004): 537-541.
Chicago
Tanaka, M., Grossman, H. B."Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells". Oncology Reports 11, no. 2 (2004): 537-541. https://doi.org/10.3892/or.11.2.537